{"id":70123,"date":"2026-07-16T18:44:28","date_gmt":"2026-07-16T10:44:28","guid":{"rendered":"https:\/\/flcube.com\/?p=70123"},"modified":"2026-07-16T18:44:30","modified_gmt":"2026-07-16T10:44:30","slug":"innocare-pharmas-soficitinib-meets-primary-endpoint-in-phase-iii-atopic-dermatitis-trial-as-highly-selective-tyk2-inhibitor","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70123","title":{"rendered":"InnoCare Pharma&#8217;s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>InnoCare Pharma Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9969:HKG\">HKG: 9969<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688428:SHA\">SHA: 688428<\/a>) announced today that the <strong>Phase III registrational clinical trial<\/strong> of its self-developed drug <strong>soficitinib (ICP-332)<\/strong> for the treatment of <strong>adult patients with moderate-to-severe atopic dermatitis (AD)<\/strong> has successfully met its primary endpoint. The oral TYK2 inhibitor demonstrates approximately <strong>400-fold selectivity against JAK2<\/strong>, potentially reducing safety risks associated with non-selective JAK inhibitors.<\/p>\n\n\n\n<h2 id=\"h-clinical-milestone-key-details\" class=\"wp-block-heading\">Clinical Milestone | Key Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>InnoCare Pharma Limited (HKG: 9969, SHA: 688428)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>Soficitinib (ICP-332)<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase III registrational<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Moderate-to-severe atopic dermatitis (AD)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Adult patients<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Successfully met<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>July 16, 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 id=\"h-molecular-characteristics\" class=\"wp-block-heading\">Molecular Characteristics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> Novel, highly selective, oral TYK2 (tyrosine kinase 2) inhibitor<\/li>\n\n\n\n<li><strong>Selectivity Profile:<\/strong> Approximately <strong>400-fold selectivity against JAK2<\/strong><\/li>\n\n\n\n<li><strong>Development Status:<\/strong> Self-developed by InnoCare Pharma<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Oral dosing<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-therapeutic-innovation\" class=\"wp-block-heading\">Therapeutic Innovation<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Soficitinib represents a next-generation approach to autoimmune disease treatment:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Targeted Inhibition:<\/strong> Selective blockade of TYK2 signaling pathway involved in inflammatory responses<\/li>\n\n\n\n<li><strong>Safety Advantage:<\/strong> High selectivity designed to minimize adverse events associated with pan-JAK inhibition<\/li>\n\n\n\n<li><strong>Broad Applicability:<\/strong> Potential therapeutic option across multiple autoimmune conditions<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-multi-indication-development-strategy\" class=\"wp-block-heading\">Multi-Indication Development Strategy<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The drug is currently undergoing clinical development for <strong>five autoimmune indications<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Atopic dermatitis<\/strong> (Phase III \u2013 primary endpoint met)<\/li>\n\n\n\n<li><strong>Vitiligo<\/strong> (ongoing clinical trials)<\/li>\n\n\n\n<li><strong>Prurigo nodularis<\/strong> (ongoing clinical trials)<\/li>\n\n\n\n<li><strong>Chronic spontaneous urticaria<\/strong> (ongoing clinical trials)<\/li>\n\n\n\n<li><strong>Psoriasis<\/strong> (ongoing clinical trials)<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-significance-amp-market-opportunity\" class=\"wp-block-heading\">Strategic Significance &amp; Market Opportunity<\/h2>\n\n\n\n<h3 id=\"h-atopic-dermatitis-market-context\" class=\"wp-block-heading\">Atopic Dermatitis Market Context<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence:<\/strong> Affects 10-20% of children and 1-3% of adults globally<\/li>\n\n\n\n<li><strong>Treatment Evolution:<\/strong> Shift from topical therapies to systemic biologics and small molecules<\/li>\n\n\n\n<li><strong>Current Options:<\/strong> Dupilumab (biologic), JAK inhibitors (upadacitinib, abrocitinib), corticosteroids<\/li>\n\n\n\n<li><strong>Market Size:<\/strong> Global AD therapeutics market projected to reach <strong>$12+ billion by 2030<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-differentiation\" class=\"wp-block-heading\">Competitive Differentiation<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Soficitinib&#8217;s <strong>400-fold TYK2 selectivity<\/strong> positions it favorably in the competitive JAK\/TYK2 inhibitor landscape:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Safety Profile:<\/strong> Reduced risk of hematological and cardiovascular adverse events compared to non-selective JAK inhibitors<\/li>\n\n\n\n<li><strong>Regulatory Environment:<\/strong> Enhanced safety profile addresses recent FDA\/EMA safety concerns with JAK inhibitors<\/li>\n\n\n\n<li><strong>Patient Access:<\/strong> Oral administration offers convenience advantages over injectable biologics<\/li>\n\n\n\n<li><strong>Pricing Potential:<\/strong> Premium positioning based on improved safety profile<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-tyk2-target-validation\" class=\"wp-block-heading\">TYK2 Target Validation<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">TYK2 inhibition has emerged as a <strong>validated therapeutic approach<\/strong> following the success of deucravacitinib in psoriasis:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Upstream Targeting:<\/strong> TYK2 mediates signaling of multiple cytokines (IL-12, IL-23, Type I IFNs) involved in AD pathogenesis<\/li>\n\n\n\n<li><strong>Balanced Efficacy\/Safety:<\/strong> Selective TYK2 inhibition provides anti-inflammatory effects while preserving other JAK family functions<\/li>\n\n\n\n<li><strong>Broad Therapeutic Potential:<\/strong> Single molecule applicable across multiple Th2-mediated and autoimmune conditions<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-regulatory-and-commercial-implications\" class=\"wp-block-heading\">Regulatory and Commercial Implications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The successful Phase III primary endpoint achievement represents a <strong>pivotal milestone<\/strong> for InnoCare Pharma:<\/p>\n\n\n\n<h3 id=\"h-regulatory-pathway\" class=\"wp-block-heading\">Regulatory Pathway<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Registrational Trial:<\/strong> Data supports New Drug Application (NDA) submissions in major markets<\/li>\n\n\n\n<li><strong>Expedited Review Potential:<\/strong> First-in-class or best-in-class positioning may qualify for priority review designations<\/li>\n\n\n\n<li><strong>Global Development:<\/strong> Strong intellectual property position supports international regulatory filings<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-commercial-strategy\" class=\"wp-block-heading\">Commercial Strategy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lead Indication:<\/strong> Atopic dermatitis serves as gateway indication for broader autoimmune portfolio<\/li>\n\n\n\n<li><strong>Pipeline Leverage:<\/strong> Success in AD de-risks development in four additional indications<\/li>\n\n\n\n<li><strong>Partnership Opportunities:<\/strong> Phase III success enhances attractiveness for global commercial partnerships<\/li>\n\n\n\n<li><strong>Market Entry Timing:<\/strong> Positions InnoCare to capture share in growing oral AD therapeutics market<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-looking-strategic-impact\" class=\"wp-block-heading\">Forward-Looking Strategic Impact<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This Phase III success validates InnoCare&#8217;s <strong>internal drug discovery capabilities<\/strong> and establishes soficitinib as a potential cornerstone asset:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Validation:<\/strong> Demonstrates successful application of selective kinase inhibitor design principles<\/li>\n\n\n\n<li><strong>Portfolio Diversification:<\/strong> Expands beyond oncology focus into high-value autoimmune diseases<\/li>\n\n\n\n<li><strong>Shareholder Value Creation:<\/strong> Significant value inflection point with registrational trial success<\/li>\n\n\n\n<li><strong>Global Ambition:<\/strong> Positions InnoCare as competitive player in international autoimmune therapeutics market<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The multi-indication development strategy creates multiple value creation opportunities, with atopic dermatitis serving as the initial commercial launch indication followed by potential label expansions into vitiligo, psoriasis, and other autoimmune conditions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and market opportunities. Actual results may differ due to risks including regulatory decisions, competitive dynamics, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688428_20260716_NBSZ.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688428_20260716_NBSZ.\"><\/object><a id=\"wp-block-file--media-891fdfda-afc4-4fbf-8df2-66317a626f14\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688428_20260716_NBSZ.pdf\">688428_20260716_NBSZ<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688428_20260716_NBSZ.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-891fdfda-afc4-4fbf-8df2-66317a626f14\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced today that the Phase III registrational clinical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[65,17,919,327,920],"class_list":["post-70123","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-clinical-trial-results","tag-hkg-9969","tag-innocare-pharma","tag-sha-688428"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>InnoCare Pharma&#039;s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced today that the Phase III registrational clinical trial of its self-developed drug soficitinib (ICP-332) for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD) has successfully met its primary endpoint. The oral TYK2 inhibitor demonstrates approximately 400-fold selectivity against JAK2, potentially reducing safety risks associated with non-selective JAK inhibitors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70123\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InnoCare Pharma&#039;s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor\" \/>\n<meta property=\"og:description\" content=\"InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced today that the Phase III registrational clinical trial of its self-developed drug soficitinib (ICP-332) for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD) has successfully met its primary endpoint. The oral TYK2 inhibitor demonstrates approximately 400-fold selectivity against JAK2, potentially reducing safety risks associated with non-selective JAK inhibitors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70123\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-16T10:44:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-16T10:44:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70123#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70123\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"InnoCare Pharma&#8217;s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor\",\"datePublished\":\"2026-07-16T10:44:28+00:00\",\"dateModified\":\"2026-07-16T10:44:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70123\"},\"wordCount\":647,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Clinical trial results\",\"HKG: 9969\",\"InnoCare Pharma\",\"SHA: 688428\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70123#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70123\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70123\",\"name\":\"InnoCare Pharma's Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-16T10:44:28+00:00\",\"dateModified\":\"2026-07-16T10:44:30+00:00\",\"description\":\"InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced today that the Phase III registrational clinical trial of its self-developed drug soficitinib (ICP-332) for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD) has successfully met its primary endpoint. The oral TYK2 inhibitor demonstrates approximately 400-fold selectivity against JAK2, potentially reducing safety risks associated with non-selective JAK inhibitors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70123#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70123\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70123#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InnoCare Pharma&#8217;s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"InnoCare Pharma's Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor - Insight, China&#039;s Pharmaceutical Industry","description":"InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced today that the Phase III registrational clinical trial of its self-developed drug soficitinib (ICP-332) for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD) has successfully met its primary endpoint. The oral TYK2 inhibitor demonstrates approximately 400-fold selectivity against JAK2, potentially reducing safety risks associated with non-selective JAK inhibitors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70123","og_locale":"en_US","og_type":"article","og_title":"InnoCare Pharma's Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor","og_description":"InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced today that the Phase III registrational clinical trial of its self-developed drug soficitinib (ICP-332) for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD) has successfully met its primary endpoint. The oral TYK2 inhibitor demonstrates approximately 400-fold selectivity against JAK2, potentially reducing safety risks associated with non-selective JAK inhibitors.","og_url":"https:\/\/flcube.com\/?p=70123","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-16T10:44:28+00:00","article_modified_time":"2026-07-16T10:44:30+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70123#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70123"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"InnoCare Pharma&#8217;s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor","datePublished":"2026-07-16T10:44:28+00:00","dateModified":"2026-07-16T10:44:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70123"},"wordCount":647,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Clinical trial results","HKG: 9969","InnoCare Pharma","SHA: 688428"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70123#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70123","url":"https:\/\/flcube.com\/?p=70123","name":"InnoCare Pharma's Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-16T10:44:28+00:00","dateModified":"2026-07-16T10:44:30+00:00","description":"InnoCare Pharma Limited (HKG: 9969, SHA: 688428) announced today that the Phase III registrational clinical trial of its self-developed drug soficitinib (ICP-332) for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD) has successfully met its primary endpoint. The oral TYK2 inhibitor demonstrates approximately 400-fold selectivity against JAK2, potentially reducing safety risks associated with non-selective JAK inhibitors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70123#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70123"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70123#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"InnoCare Pharma&#8217;s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70123"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70123\/revisions"}],"predecessor-version":[{"id":70126,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70123\/revisions\/70126"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70123"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70123"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}